Top Suppliers:I want be here
Related CAS#:
50-32-8 192-97-2
20928-82-9 39000-82-3
25167-89-9 24496-65-9
98151-92-9 21248-00-0
70021-98-6 24027-83-6
1158522-08-7 940364-43-2
134104-43-1 131615-57-1
6906-52-1 930439-75-1
1018584-77-4 1375289-11-4
849349-65-1 309735-80-6

50-32-8

50-32-8 structure
50-32-8 structure
Name benzo[a]pyrene
Synonyms UNII-3417WMA06D
Benzo[a]pyrene (Ames grade)
Benzo[A]Pyrene
Benzo(d,e,f)chrysene
Benzo(a)pyrene
Benzo[a]pyren
benzo[1,2,5]thiadiazole-4-sulfonyl chloride
2,1,3-benzothiadiazol-4-sulfonyl chloride
3,4-Benzpyrene
3,4-Benz(a)pyrene
4,5-BENZPYRENE
2,1,3-Benzothiadiazole,4-chlorosulfonyl
3,4-benzopyrene
2,1,3-benzothiadiazole-4-sulphonyl chloride
1,2-Benzpyrene (VAN)
Benzo[pqr]tetraphene
Benzopyrene
4-Chlorosulfonyl-2,1,3-benzothiadiazole
2,1,3-benzothiadiazole-4-sulfonylchloride
3,4-Benzo(a)pyrene
Benzo-2,1,3-thiadiazole-4-sulphonyl chloride
Benzo[c][1,2,5]thiadiazole-4-sulfonyl chloride
EINECS 200-028-5
benz[a]pyrene
benzo[2,1,3]thiadiazole-4-sulfonyl chloride
6,7-Benzopyrene
MFCD00003602
1,2-Benzpyrene
Description Benzo[a]pyrene shows lung carcinogenicity in animal models, and it is frequently used in chemoprevention studies.
Related Catalog
In Vivo Statistically significant decrease is observed at 7 weeks in females receiving 1.0 mg Benzo[a]pyrene (B[a]P) compare with the vehicle group. As lung tumorigenesis induced by Benzo[a]pyrene is dose dependent in female A/J mice. The incidence of hyperplasia values in females treating with 0.25, 0.50, and 1.0 mg Benzo[a]pyrene are significantly higher than in the vehicle-treated group. The incidence of adenoma in females receiving 1.0 mg Benzo[a]pyrene is significantly higher than in the vehicle group. The multiplicity of hyperplasia in females receiving 0.50 or 1.0 mg Benzo[a]pyrene is significantly higher than in the vehicle group. The multiplicity of adenoma in the group treated with 1.0 mg is also significantly higher than in the vehicle group. The incidences of hyperplasia and adenoma in female A/J mice are significantly increased by Benzo[a]pyrene in a dose-dependent manner[1]. Benzo[a]pyrene induces an average of 9.38±1.75 tumors with an average tumor load of 19.53±3.81 mm3 (P<0.05 compare to control). Benzo[a]pyrene administration significantly (P<0.05) decreases cAMP levels in tumors with adjacent lung tissues. The expression level of PDE4D gene is also increased by Benzo[a]pyrene administration[2].
Animal Admin Female A/J mice are randomized into eight groups (n=8): (i) control; (ii)Benzo[a]pyrene (B(a)P)+vehicle (methocel); (iii) Benzo[a]pyrene+roflumilast 1 mg/kg; (iv) Benzo[a]pyrene+roflumilast 5 mg/kg; (v) Benzo[a]pyrene+aerozolie phosphate-buffer saline (PBS); (vi) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL; (vii) Benzo[a]pyrene+aerosolized budesonide 2.25 mg/mL+roflumilast 1 mg/kg; and (viii) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL+roflumilast 5 mg/kg groups. A single dose of Benzo[a]pyrene in corn oil is given intraperitoneally once at 100 mg/kg body weight. Roflumilast (1 or 5 mg/kg) is started 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (3 days/week) via oral gavage. Mice in the Benzo[a]pyrene+vehicle group are treated with an equal volume of methocel as solvent control. Aerosolizing budesonide is administrated by inhaling route as an aerosol at a dose of 2.25 mg/mL for 2 min per application at 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (5 days/week). PBS is also used as solvent control by inhaling route after Benzo[a]pyrene administration in the Benzo[a]pyrene+PBS group. Mice are killed at 28 weeks after exposure to Benzo[a]pyrene. Their lungs are excised and stored at -70 °C[2].
References

[1]. Saeko Onami, et al. Dosimetry for lung tumorigenesis induced by urethane, 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and benzo[a]pyrene (B[a]P) in A/JJmsSlc mice. J Toxicol Pathol. 2017 Jul; 30(3): 209–216.

[2]. Yeo CD, et al. Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model. Eur J Pharmacol. 2017 Oct 5;812:189-
Density 1.3±0.1 g/cm3
Boiling Point 495.0±0.0 °C at 760 mmHg
Melting Point 177-180°C
Molecular Formula C20H12
Molecular Weight 252.309
Flash Point 228.6±13.7 °C
Exact Mass 252.093903
LogP 6.40
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.887
Stability Stable. Incompatible with strong oxidizing agents.
Symbol GHS07 GHS08 GHS09
GHS07, GHS08, GHS09
Signal Word Danger
Hazard Statements H317-H340-H350-H360FD-H410
Supplemental HS Repeated exposure may cause skin dryness or cracking.
Precautionary Statements P201-P273-P280-P308 + P313-P333 + P313-P501
Personal Protective Equipment Eyeshields;Faceshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter
Hazard Codes F:Flammable;T:Toxic;
Risk Phrases R45;R11;R38;R50/53;R65;R67
Safety Phrases S45-S53-S61-S60-S26-S62
RIDADR 2811
RTECS DJ3675000
Packaging Group III
Hazard Class 6.1
HS Code 2902909090
HS Code 2902909090
Summary 2902909090 other aromatic hydrocarbons。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:2.0%。General tariff:30.0%

Chemsrc provides CAS#:50-32-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 50-32-8 | Chemsrc address: https://www.chemsrc.com/en/baike/414988.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved